Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole K. Jeppesen, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 971-984
Closed Access | Times Cited: 757

Showing 76-100 of 757 citing articles:

Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 43
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Yiming Mu, Xiao-lei Bao, Freddy G. Eliaschewitz, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 184-195
Closed Access | Times Cited: 38
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal, Harold Bays, Sébastien Czernichow, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 17, pp. 1573-1583
Closed Access | Times Cited: 37
Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
Jianxing Zhou, You Zheng, Baohua Xu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 33
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 31
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
GLP-1 agonists: A review for emergency clinicians
Brit Long, Jessica Pelletier, Alex Koyfman, et al.
The American Journal of Emergency Medicine (2024) Vol. 78, pp. 89-94
Closed Access | Times Cited: 22
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians
Tyler Drake, Adrienne Landsteiner, Lisa Langsetmo, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 5, pp. 618-632
Closed Access | Times Cited: 22
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Barbara McGowan, Jens Meldgaard Bruun, Matt Capehorn, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 9, pp. 631-642
Closed Access | Times Cited: 22
Sex- and Gender-Related Differences in Obesity: From Pathophysiological Mechanisms to Clinical Implications
Andrijana Koceva, Rok Herman, Andrej Janež, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7342-7342
Open Access | Times Cited: 21
Pharmacotherapy for obesity: moving towards efficacy improvement
Walmir Coutinho, Bruno Halpern
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 20
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 20
Cellular mechanisms of incretin hormone secretion
Marta Santos-Hernández, Frank Reimann, Fiona M. Gribble
Journal of Molecular Endocrinology (2024) Vol. 72, Iss. 4
Open Access | Times Cited: 20
Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Xin‐Hui Pan, B.C. Tan, Yip Han Chin, et al.
Obesity (2024) Vol. 32, Iss. 5, pp. 840-856
Closed Access | Times Cited: 19
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S86-S127
Closed Access | Times Cited: 19
Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
Camille Lupiañez-Merly, Saam Dilmaghani, Kia Vosoughi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 4, pp. 475-491
Closed Access | Times Cited: 18
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang
The Kaohsiung Journal of Medical Sciences (2024) Vol. 40, Iss. 3, pp. 212-220
Open Access | Times Cited: 18
Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity
Naveed Sattar, Calum Presslie, Martin K. Rutter, et al.
Diabetes Care (2024) Vol. 47, Iss. 4, pp. 531-543
Open Access | Times Cited: 18
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction
Subodh Verma, Javed Butler, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 9, pp. 773-785
Open Access | Times Cited: 18
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S167-S180
Closed Access | Times Cited: 18
Therapeutic advances in obesity management: an overview of the therapeutic interventions
Moody Al Roomy, Kainat Hussain, Hawraa M. Behbehani, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 17
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology
Thomas A. Wadden, Gregory K. Brown, Christina Egebjerg, et al.
JAMA Internal Medicine (2024)
Open Access | Times Cited: 17
Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
Frederick Berro Rivera, Grace Nooriza O. Lumbang, Danielle Rose Magno Gaid, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2209-2228
Open Access | Times Cited: 16
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 16
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Vincent Chen, Timothy R. Morgan, Yaron Rotman, et al.
Hepatology (2024)
Open Access | Times Cited: 16

Scroll to top